CurrentRheuma — Pediatric rheumatology

Early life infections, antibiotics and later risk of juvenile idiopathic arthritis: evidence from two Scandinavian birth cohorts with exploratory genetic analyses

2026-11-13T11:15:45.584Z

Meta-analysis · RMD Open, 2026.

Long-term efficacy and safety of upadacitinib in patients with polyarticular-course juvenile idiopathic arthritis: 48 week results from the SELECT-YOUTH open-label study

2026-11-13T09:15:36.833Z

Research article · Rheumatology (Oxford), 2026.

ERN-RITA/PReS recommendations for the diagnosis, classification, monitoring, and treatment of childhood idiopathic (primary) angiitis of the central nervous system

2026-11-13T06:15:29.260Z

Guideline or statement · Ann Rheum Dis, 2026.

Combination targeted therapy with Janus kinase inhibition plus biologic agents in refractory JIA: an international multi-centre case series

2026-11-12T11:15:54.044Z

Cohort study · Rheumatology (Oxford), 2026.

Creatine and CoQ10 with physical activity on muscle function in children with myositis: a proof-of-concept trial

2026-11-12T11:15:54.044Z

Randomized controlled trial · Rheumatology (Oxford), 2026.

Predicting Inactive Disease in Juvenile Idiopathic Arthritis: A Dynamic Machine Learning Approach

2026-11-07T05:15:27.138Z

Diagnostic or prognostic study · Arthritis Rheumatol, 2026.

Synovial Tissue‐Guided Interleukin‐17A Inhibition for Refractory Arthritis in a Patient With Systemic Juvenile Idiopathic Arthritis

2026-11-07T05:15:27.138Z

Research article · Arthritis Rheumatol, 2026.

Association of platelet level and white blood cell level with coronary artery lesions persistence among patients with Kawasaki disease

2026-11-05T13:24:18.717Z

Research article · Rheumatology (Oxford), 2026.

Discontinuation of systemic medications in Juvenile Idiopathic Arthritis - Risks and Remission: A Systematic Review and Meta-Analysis

2026-11-05T13:24:18.717Z

Meta-analysis · J Rheumatol, 2026.

Effectiveness of second-line biologics in juvenile idiopathic arthritis: the IIBIOJIA Study

2026-11-05T13:24:18.717Z

Cohort study · RMD Open, 2026.

Impact of sugar- and artificially sweetened beverages on bone health: a systematic review, meta-analysis, and network meta-analysis among children, adolescents, and adults

2026-11-05T13:24:18.717Z

Meta-analysis · Osteoporos Int, 2026.

Krebs Von Den Lungen-6 as a biomarker for lung disease activity and diagnosis in systemic juvenile idiopathic arthritis

2026-11-05T13:24:18.717Z

Diagnostic or prognostic study · Rheumatology (Oxford), 2026.

Paint me a picture: illustrating the psychosocial impact of different juvenile idiopathic arthritis categories

2026-11-05T13:24:18.717Z

Cohort study · Rheumatology (Oxford), 2026.

Predictors of Clinical Remission in Children With Polyarticular Juvenile Idiopathic Arthritis Treated With Abatacept

2026-11-05T13:24:18.717Z

Research article · J Rheumatol, 2026.

Conductive and sensorineural hearing impairment in juvenile idiopathic arthritis: a systematic review and meta-analysis

2026-11-05T13:10:58.883Z

Meta-analysis · Rheumatology (Oxford), 2026.

An iceberg I can’t handle: a qualitative inquiry on perceptions towards paediatric rheumatology among healthcare workers in Kenya

2026-11-04T23:51:38.466Z

Research article · Pediatr Rheumatol Online J, 2023. Knowledge, attitudes and practices towards paediatric rheumatology: Gaps in knowledge of paediatric rheumatology among healthcare workers, contributing to delayed diagnosis and poor management

Axial involvement in enthesitis-related arthritis: results from a single-center cohort

2026-11-04T23:51:38.466Z

Cohort study · Pediatr Rheumatol Online J, 2023. Clinical characteristics and treatment: Age at disease onset tended to be higher in axial ERA: 11.93 ± 1.72 vs 11.09 ± 1.91 years

Childhood-onset primary Sjögren’s syndrome in a tertiary center in China: clinical features and outcome

2026-11-04T23:51:38.466Z

Cohort study · Pediatr Rheumatol Online J, 2023. Clinical features of childhood-onset pSS: Fulfilled AECG criteria 27 (69.2%)

Clinical phenotypes and prognosis of cytomegalovirus infection in the pediatric systemic lupus erythematosus: a longitudinal analysis

2026-11-04T23:51:38.466Z

Cohort study · Pediatr Rheumatol Online J, 2023. CMV infection rate: CMV infection rate in pSLE cohort (109/146) 74.7%

Colchicine treatment can be discontinued in a selected group of pediatric FMF patients

2026-11-04T23:51:38.466Z

Cohort study · Pediatr Rheumatol Online J, 2023. Characteristics prior to drug cessation: Group 1 had no biallelic pathogenic MEFV mutations

Dry synovitis, a rare entity distinct from juvenile idiopathic arthritis

2026-11-04T23:51:38.466Z

Cohort study · Pediatr Rheumatol Online J, 2023. Clinical features vs RFneg-polyJIA — DS vs RFneg-polyJIA: number of joints involved (higher in DS); p = 0.0001

Effect of interleukin-1 antagonist on growth of children with colchicine resistant or intolerant FMF

2026-11-04T23:51:38.466Z

Cohort study · Pediatr Rheumatol Online J, 2023. Height percentile, before vs after anti-IL-1 treatment — After treatment vs Before treatment; p = 0.007; 19.6 ± 16% vs. 30.8 ± 23%

Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review

2026-11-04T23:51:38.466Z

Research article · Pediatr Rheumatol Online J, 2023. JIA-ACR30/50/70/90 response (% of patients, range across trials): Adalimumab: JIA-ACR30 (Week 12) 71-94%; JIA-ACR50 (Week 12) 68-90%; JIA-ACR70 (Week 12) 55-61%; JIA-ACR90 (Week 12) 39-42% · Etanercept: JIA-ACR30 (Week 12) 73-94%; JIA-ACR50 (Week 12) 53-78%; JIA-ACR70 (Week 12) 36-59%; JIA-ACR90 (Week 12) 28% · Golimumab: JIA-ACR30 (Week 16) 89%; JIA-ACR50 (Week 16) 79%; JIA-ACR70 (Week 16) 66%; JIA-ACR90 (Week 16) 36% · Infliximab: JIA-ACR30 (Week 14) 64%; JIA-ACR50 (Week 14) 50%; JIA-ACR70 (Week 14) 22%

Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study

2026-11-04T23:51:38.466Z

Cohort study · Pediatr Rheumatol Online J, 2023. Correlation between ETN dose and serum drug level: MTX r 0.35 (95% CI 0.14-0.52) · Non-MTX r 0.54 (95% CI 0.39-0.67)

Impaired cardiorespiratory and neuromuscular fitness in children and adolescents with juvenile idiopathic arthritis: a cross-sectional case–control study in the era of biologic drug therapies

2026-11-04T23:51:38.466Z

Cross-sectional study · Pediatr Rheumatol Online J, 2023. Maximal workload (Wmax/kg): JIA mean 2.80 ± 0.54 Watts · Controls mean 3.14 ± 0.50 Watts

Individual and environmental determinants associated with longer times to access pediatric rheumatology centers for patients with juvenile idiopathic arthritis, a JIR cohort study

2026-11-04T23:51:38.466Z

Cohort study · Pediatr Rheumatol Online J, 2023. Time to first pediatric rheumatology (PR) assessment: Overall median time to first PR assessment 2.4 months [1.3; 6.9]

Juvenile idiopathic arthritis patients with positive family history of autoimmune thyroid disease might benefit from serological screening: analysis of the international Pharmachild registry

2026-11-04T23:51:38.466Z

Cohort study · Pediatr Rheumatol Online J, 2023. Prevalence of AITD, median 5.5 years: AITD 96 (1.1%)

Macrophage activation syndrome in children with Kikuchi-Fujimoto disease

2026-11-04T23:51:38.466Z

Cohort study · Pediatr Rheumatol Online J, 2023. Incidence of MAS in KFD: KFD-MAS 15 (25.9%)

Multi-inflammatory syndrome in children (MIS-C) associated with COVID-19: a nursing perspective experience report from a high-income tertiary paediatric hospital context

2026-11-04T23:51:38.466Z

Research article · Pediatr Rheumatol Online J, 2023. Mean age of the children (years) 8.8

Outcome of adalimumab monotherapy in paediatric non-infectious uveitis

2026-11-04T23:51:38.466Z

Cohort study · Pediatr Rheumatol Online J, 2023. Disease control on adalimumab monotherapy: <2-step worsening in uveitis (SUN score) and no additional systemic immunosuppression, During the study period: Study subjects who met the primary outcome 23 (82.14%)

Pain-coping scale for children and their parents: a cross-sectional study in children with musculoskeletal pain

2026-11-04T23:51:38.466Z

Cross-sectional study · Pediatr Rheumatol Online J, 2023. Factors retained in both scales 4

Profiling the peripheral immune response to ex vivo TNF stimulation in untreated juvenile idiopathic arthritis using single cell RNA sequencing

2026-11-04T23:51:38.466Z

Mechanistic study · Pediatr Rheumatol Online J, 2023. 24 h: Robust immune cell-types identified 17

Risk factors for subsequent lupus nephritis in patients with juvenile-onset systemic lupus erythematosus: a retrospective cohort study

2026-11-04T23:51:38.466Z

Cohort study · Pediatr Rheumatol Online J, 2023. Predictors of subsequent LN (multivariable Cox regression), during follow-up: HR per 100 IU/ml increase in average anti-dsDNA antibody, 95% CI 1.055-1.573 1.29

Strategic use of levofolinic acid for methotrexate-induced side effects in juvenile idiopathic arthritis: a prospective observational study

2026-11-04T23:51:38.466Z

Cohort study · Pediatr Rheumatol Online J, 2023. Complete remission of gastrointestinal side effects, first visit (T1): LVF 61.9%

Subtype frequency, demographic features, treatment and outcome of Juvenile Arthritis in one Centre in Abu Dhabi in the United Arab Emirates

2026-11-04T23:51:38.466Z

Cohort study · Pediatr Rheumatol Online J, 2023. JIA subtype frequency: Oligoarticular 75 (55%) · RF-negative polyarticular 32 (23%) · ERA 10 (7%) · Psoriatic 6% · Systemic JIA 5% · Undifferentiated 2%

The effect of TNF treatment uptake on incident hospital admission in Western Australia

2026-11-04T23:51:38.466Z

Cohort study · Pediatr Rheumatol Online J, 2023. Annual incident admission rate for JIA, 1990–2012: Annual incident admission rate per 100,000 person-years 7.9 (95%CI: 7.3, 8.4)

Treatment escalation patterns to start biologics in refractory moderate juvenile dermatomyositis among members of the Childhood Arthritis and Rheumatology Research Alliance

2026-11-04T23:51:38.466Z

Cross-sectional study · Pediatr Rheumatol Online J, 2023. Treatment escalation practices for refractory moderate JDM: Would initiate a biologic after failing 1-2 non-biologic disease-modifying antirheumatic drugs (DMARDs) approximately 80%

A 5–year follow-up of pulmonary function tests in childhood-onset systemic lupus erythematosus: a single-center retrospective study

2026-11-04T23:48:14.847Z

Cohort study · Lupus, 2023. Abnormal PFTs: Abnormal PFTs 10 (23.8%)

Serum levels and significance of soluble B-cell maturation antigen in childhood-onset systemic lupus erythematosus with renal involvement

2026-11-04T23:48:14.847Z

Cross-sectional study · Lupus, 2023. Serum sBCMA levels: Serum sBCMA significantly increased in primary cSLE vs treated cSLE and HCs

Assessment of myelin oligodendrocyte glycoprotein antibodies and magnetic resonance spectroscopy in childhood-onset systemic lupus erythematosus

2026-11-04T23:43:54.165Z

Cross-sectional study · Clin Exp Rheumatol, 2022. MOG-Ab: MOG-Ab was not detected in cSLE or in healthy group

Can ultrasound help to overcome uncertainty in clinical joint assessment in juvenile idiopathic arthritis?

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2022. MSUS features of active disease (synovitis), study entry: Q-joints 54 (54.5%) · Clinically inactive joints 78 (30.8%) · Clinically active joints 114 (88.4%) · Healthy controls 2 (1.9%)

Clinical characteristics of 1020 childhood-onset systemic lupus erythematosus: data from a health centre in China

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2022. Clinical characteristics of cSLE: Female to male ratio 3.8:1

Race, ethnicity and patient-reported outcomes in childhood-onset systemic lupus erythematosus

2026-11-04T23:43:54.165Z

Cross-sectional study · Clin Exp Rheumatol, 2022. Association of race/ethnicity with PROMIS scores (multivariable linear regression), registry enrolment: No association between race/ethnicity and PROMIS scores

Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus: A multicenter study

2026-11-04T23:42:37.367Z

Cohort study · Joint Bone Spine, 2023. neuropsychiatric (NP) involvement (prevalence): jSLE patients with NP involvement 149 (13.5%)

Risk stratification using anti-citrullinated peptide antibodies (ACPA) in polyarticular subtypes of juvenile idiopathic arthritis in adulthood

2026-11-04T23:42:37.367Z

Cohort study · Joint Bone Spine, 2022. Structural damage (Sharp Van Der Heijde scores) by ACPA status — pJIA ACPA+ vs pJIA ACPA-; P<0.05; Higher erosion and total scores when adjusted on disease duration; unadjusted erosion, JSN and total scores higher but not significant

Validity of ultrasonography in detecting enthesitis in children: A systematic literature review

2026-11-04T23:42:37.367Z

Meta-analysis · Joint Bone Spine, 2023. US entheseal abnormalities: JIA patients with entheseal abnormalities on US 9.4 to 53%

Canadian Rheumatology Association Recommendations for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-associated Uveitis

2026-11-04T23:37:51.551Z

Guideline or statement · J Rheumatol, 2022.

Differentially Expressed Inflammation-Regulating MicroRNAs in Oligoarticular Juvenile Idiopathic Arthritis

2026-11-04T23:37:51.551Z

Mechanistic study · J Rheumatol, 2022. MicroRNA expression: MiR-15a-5p and miR-409-3p higher in JIA plasma than in HC plasma

Do Patterns of Early Disease Severity Predict Grade 12 Academic Achievement in Youths With Childhood-Onset Chronic Rheumatic Diseases?

2026-11-04T23:37:51.551Z

Cohort study · J Rheumatol, 2023. LAI and MAI scores (adjusted), grade 12: Severe disease 9.7% · Moderate disease 54.5% · Mild disease 35.8%

Patient-Reported Outcomes Among Transition-Age Young Adults With Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry

2026-11-04T23:37:51.551Z

Cohort study · J Rheumatol, 2022. Characteristics by transfer status: Complete transfer 54%